Could at-home brain stimulation reduce SSRI reliance?

If you or a loved one lives with depression, PMDD, postpartum depression, or any of the conditions where a doctor's first move is to reach for a selective serotonin reuptake inhibitor (SSRI), a new 2026 New York Times feature will be worth your attention. The piece, published April 28, 2026. asks whether at-home brain stimulation could give psychiatry an alternative to SSRIs, which have been the default for depression since the late 1980s. One in six Americans is now on one.

As Sarah Lisanby of Duke University tells the New York Times, neuromodulation is "a whole new way of intervening", and "we're just scratching the surface of what's going to be possible."

At-home brain stimulation is approved by the FDA

In December 2025, the U.S. Food and Drug Administration approved Flow Neuroscience's at-home headset as a first-line treatment for moderate-to-severe major depressive disorder, which is the first home-use brain stimulation device to receive that indication (it has been approved in the European Union and the United Kingdom since 2019). Flow Neuroscience’s device uses the exact same technology as Samphire’s Nettle™ and Lutea™, transcranial direct current stimulation (tDCS).

The NYT feature discusses what this technology actually means for clinical practice, which is about to be fundamentally disrupted.

How does it actually work?

Depression is increasingly framed as partly a disease of impaired neural connectivity, i.e. circuits that should fire together don't. Gentle electrical stimulation through electrodes placed on the scalp lowers the threshold for the targeted neurons to fire, encouraging the kind of activity those circuits are missing. Mark George's image in the NYT is striking: electricity is "the brain's lingua franca."

The reported side effects are transient and mild: mild skin irritation, sometimes - headaches or some transient ringing in the ears. Crucially, no memory effects of the kind associated with electroconvulsive therapy. As Prof George says: "This is as far from ECT as a jet engine is from my bicycle." All of these side effects are negligible when compared to side effects of SSRIs or COCs, often used to manage hormone-related mood symptoms in women.

Where brain stimulation sits in the toolkit

• Electroconvulsive therapy (ECT) remains the standard for severe, treatment-resistant depression, but it requires anaesthesia, induces seizures, and can cause memory issues (it’s thousands of times stronger than tDCS!).
• Transcranial Magnetic Stimulation (TMS) is FDA-approved for depression, OCD, migraines, and smoking cessation: it’s safe and effective, but requires expensive clinic-based equipment and multiple visits per week.
• At-home brain stimulation (tDCS) the category that is now leading the way, including Samphire’s products, is the first of these to reach the bedside in a more widely accessible, safe and effective way.

Anna Wexler of the University of Pennsylvania (medical ethics) tells the NYT that the approval "legitimizes the therapy itself as a medical therapy, not just something sold online for wellness or enhancement."

Why this matters for women's mental health

The NYT feature opens with Sophie Davies, 34, who developed severe postpartum OCD and depression in East Anglia and was using a brain stimulation headband alongside an antidepressant. That's not incidental. Women are more likely than men to be prescribed SSRIs, and conditions like premenstrual dysphoric disorder (PMDD), postpartum depression, and the depression that often accompanies endometriosis and other physical conditions sit squarely in the population that gets an SSRI as a first move.

Somayya Kajee, a psychiatrist in Norwich, tells the Times she is using brain stimulation to help patients taper off antidepressants or avoid starting them, including patients with ADHD or autism who don't want to add an SSRI. That's a meaningful shift in what the first conversation with a psychiatrist might look like.

Having worked with women noticing these brain changes in response to hormones for years now, we know that products like Nettle™ and Lutea™ have been transformative in giving women control over their lives, from the comfort of their homes.

The bigger question

The NYT's central thesis is that at-home brain stimulation could either slot into the existing pill-centric model ("our brains are so pharmaceutically inclined," Prof George comments) or push psychiatry past serotonin-deficiency thinking toward a more plasticity-based model of, in his phrase, "getting the brain unstuck."

That second framing maps directly onto the brain-first model Samphire works from. Mood, pain, and cognition all depend on circuits that can be nudged toward different patterns of activity. The mechanism behind devices like Flow, using gentle electrical stimulation to lower the firing threshold of targeted neurons, is the same family of approach Samphire is investigating in women's health, where Nettle™ and Lutea™ target the central mood and pain processing circuits implicated in PMS and menstrual pain. Samphire's Nettle™ clinical trial reported a 53% reduction in pain across one menstrual cycle, improvements in mood linked with PMDD, and Nettle™ is currently in NHS-trust collaborations as one of the first at-home neurotechnology trials for endometriosis pain.

Bottom line

A new 2026 NYT feature on Flow's December 2025 FDA approval reads less as a verdict on one device and more as a snapshot of a category that has finally arrived. The evidence is now real, the regulatory door is now open, and a generation of women whose first-line option has been an SSRI may, within a few years, have a different first conversation with their psychiatrist.

Frequently asked questions

Is at-home brain stimulation the same as ECT?

No. Electroconvulsive therapy (ECT) uses high-current electricity under anaesthesia to induce a brief therapeutic seizure and can cause memory effects. At-home brain stimulation uses a weak, low-amplitude current (about 2 milliamps) delivered through scalp electrodes for 20–30 minute sessions. The reported side effects are always mild and transient.

Did the FDA actually approve a brain stimulation device for depression?

Yes. In December 2025, the U.S. Food and Drug Administration granted premarket approval to Flow Neuroscience's at-home brain stimulation device as a first-line treatment for moderate-to-severe major depressive disorder, in adults who are not treatment-refractory. The device will be prescription-only in the U.S., with a planned launch in the second quarter of 2026. Samphire already has a device available for women struggling with hormone-related brain effects (Lutea™) in the US, and a medical treatment for PMS and menstrual pain (Nettle™) in Europe that is HSA/FSA eligible.

Why is this especially relevant to women's mental health?

Women are more likely than men to receive an SSRI prescription, and conditions like PMDD, postpartum depression, and the depression that often accompanies endometriosis sit firmly in that pattern. A non-pharmaceutical, brain-targeted option, particularly one that can be used at home, opens a different conversation for women who haven't been served well by the SSRI-first pathway.

How does Samphire's research relate?

Samphire's brain stimulation research focuses on women's health rather than depression specifically. Nettle™, currently in NHS-trust collaborations, targets the central pain and mood processing circuits implicated in PMS, menstrual pain, and endometriosis-related pain - a 53% reduction in pain was reported across one menstrual cycle in Nettle™'s clinical trial. The mechanism is the same family of brain stimulation as Flow, applied to a different clinical question and with a special focus on supporting women and their needs.